ATS GUIDELINES Bundle

Severe Asthma

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/592884

Contents of this Issue

Navigation

Page 14 of 15

13 Table 11. Interpretation of Recommendations and Quality of Evidence Implications for Strong recommendation Conditional recommendation Patients Most individuals in this situation would want the recommended course of action, and only a small proportion would not. e majority of individuals in this situation would want the suggested course of action, but many would not. Clinicians • Most individuals should receive the intervention. • Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. • Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. • Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. • Decision aids may be useful in helping individuals to make decisions consistent with their values and preferences. Policy makers e recommendation can be adopted as policy in most situations. Policy making will require substantial debate and involvement of various stakeholders. Table 10. Long-Term Control Medications (continued) Generic (Brand) Dosage Form Dose Leukotriene modifiers Montelukast (Singulair ® ) 10 mg tablet 4, 5 mg chewable tablets 4 mg oral granules packet 6–14 yr: 5 mg chewable tablet qhs >14 yr: 10 mg tablet qhs Zafirlukast (Accolate ® ) 10, 20 mg tablet 40 mg/d (20 mg bid) 1 h before or 2 h aer meals Zileuton (Zyflo CR ® ) 600 mg tablet 1200 mg bid Methylxanthines Serum monitoring is important. Maintain serum concentrations of 5–15 mcg/mL at steady state. eophylline (Slo-Phyllin ® , eo-24 ® , eolair ® , Uniphyl ® , others) Liquids, sustained release tablets, capsules Starting dose for children and adults >45 kg : 300–600 mg/day qd for 3 days, then 400–600 mg qd

Articles in this issue

view archives of ATS GUIDELINES Bundle - Severe Asthma